BR0312913A - Ativo de biciclo-pirazóis como inibidores de cinase, processo para sua preparação e composições farmacêuticas compreendendo o mesmo - Google Patents
Ativo de biciclo-pirazóis como inibidores de cinase, processo para sua preparação e composições farmacêuticas compreendendo o mesmoInfo
- Publication number
- BR0312913A BR0312913A BR0312913-6A BR0312913A BR0312913A BR 0312913 A BR0312913 A BR 0312913A BR 0312913 A BR0312913 A BR 0312913A BR 0312913 A BR0312913 A BR 0312913A
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- pharmaceutical compositions
- same
- kinase inhibitors
- bicyclo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
"ATIVO DE BICICLO-PIRAZóIS COMO INIBIDORES DE CINASE, PROCESSO PARA SUA PREPARAçãO E COMPOSIçõES FARMACêUTICAS COMPREENDENDO O MESMO". A presente invenção provê um método para tratamento de doenças causadas por e/ou associadas com uma atividade de cinase de proteína alterada, o qual compreende administrar a um mamífero com necessidade uma quantidade eficaz de pirrol-pirazol e pirazol-azepina. A invenção também provê pirrol-pirazóis e pirazol-azepina específicos, intermediários úteis, uma biblioteca compreendendo pelo menos dois deles, um processo para sua preparação e as composições farmacêuticas contendo-os, que são úteis no tratamento de doenças causadas por e/ou associadas com uma atividade de cinase de proteína alterada tal como câncer, distúrbios celulares proliferativos, infecções virais, doenças autoimunes e distúrbios neurodegenerativos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39812002P | 2002-07-25 | 2002-07-25 | |
PCT/EP2003/007851 WO2004013144A1 (en) | 2002-07-25 | 2003-07-16 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0312913A true BR0312913A (pt) | 2005-07-12 |
Family
ID=31495716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0312913-6A BR0312913A (pt) | 2002-07-25 | 2003-07-16 | Ativo de biciclo-pirazóis como inibidores de cinase, processo para sua preparação e composições farmacêuticas compreendendo o mesmo |
Country Status (8)
Country | Link |
---|---|
US (1) | US20060135508A1 (pt) |
EP (1) | EP1527074A1 (pt) |
JP (1) | JP2005537290A (pt) |
AU (1) | AU2003244649A1 (pt) |
BR (1) | BR0312913A (pt) |
CA (1) | CA2493637A1 (pt) |
MX (1) | MXPA05000945A (pt) |
WO (1) | WO2004013144A1 (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004283196B2 (en) * | 2003-09-17 | 2011-08-25 | Janssen Pharmaceutica, N.V. | Fused heterocyclic compounds |
WO2005030776A1 (en) * | 2003-09-23 | 2005-04-07 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrrole derivatives as protein kinase inhibitors |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
KR100919343B1 (ko) | 2005-01-10 | 2009-09-25 | 화이자 인코포레이티드 | 키네이스 억제제로서 피롤로피라졸 |
GB0513886D0 (en) | 2005-07-06 | 2005-08-10 | Glaxo Group Ltd | Novel compounds |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
CA2634381C (en) | 2005-12-21 | 2011-03-08 | Pfizer Products Inc. | Carbonylamino pyrrolopyrazoles, potent kinase inhibitors |
JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
JP5063815B2 (ja) | 2008-11-25 | 2012-10-31 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 抗腫瘍および抗神経変性剤としての二環式ピラゾールおよびイソオキサゾール誘導体 |
KR101787116B1 (ko) | 2009-01-28 | 2017-10-18 | 케러 테라퓨틱스, 인코포레이티드 | 바이시클릭 피라졸로-헤테로사이클 |
US7741350B1 (en) | 2009-01-28 | 2010-06-22 | Cara Therapeutics, Inc. | Bicyclic pyrazolo-heterocycles |
WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
JO3773B1 (ar) | 2013-03-14 | 2021-01-31 | Janssen Pharmaceutica Nv | معدلات p2x7 |
US9708334B2 (en) | 2014-04-24 | 2017-07-18 | Dart Neuroscience (Cayman) Ltd. | Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors |
EP3215500A1 (en) | 2014-11-05 | 2017-09-13 | Dart NeuroScience (Cayman) Ltd. | Substituted azetidinyl compounds as glyt1 inhibitors |
EP3224258B1 (en) | 2014-11-27 | 2019-08-14 | Genentech, Inc. | 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
US9550779B2 (en) * | 2014-12-30 | 2017-01-24 | Novira Therapeutics, Inc. | Derivatives and methods of treating hepatitis B infections |
CN109476663B (zh) | 2016-05-24 | 2021-11-09 | 基因泰克公司 | 用于治疗癌症的吡唑并吡啶衍生物 |
EA201992215A1 (ru) | 2017-03-20 | 2020-02-06 | Форма Терапьютикс, Инк. | Пирролопирроловые композиции в качестве активаторов пируваткиназы (pkr) |
EP3852791A4 (en) | 2018-09-19 | 2022-06-15 | Forma Therapeutics, Inc. | ACTIVATION OF PYRUVATE KINASE R |
US20220031671A1 (en) | 2018-09-19 | 2022-02-03 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
US20200102311A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol Lipase Modulators |
EP3856178A1 (en) | 2018-09-28 | 2021-08-04 | Janssen Pharmaceutica NV | Monoacylglycerol lipase modulators |
EP4038070A1 (en) | 2019-09-30 | 2022-08-10 | Janssen Pharmaceutica NV | Radiolabelled mgl pet ligands |
TW202140465A (zh) | 2020-02-10 | 2021-11-01 | 比利時商健生藥品公司 | 單醯基甘油脂酶調節劑 |
KR20220158785A (ko) | 2020-03-26 | 2022-12-01 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제로서의 아미노사이클로부탄 |
KR20220157999A (ko) | 2020-03-26 | 2022-11-29 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제 |
WO2021191384A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Aryl piperidines as monoacylglycerol lipase modulators |
AU2021241888A1 (en) | 2020-03-26 | 2022-09-29 | Janssen Pharmaceutica Nv | Azaspirocycles as monoacylglycerol lipase modulators |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9608435D0 (en) * | 1996-04-24 | 1996-06-26 | Celltech Therapeutics Ltd | Chemical compounds |
DE69834842T2 (de) * | 1997-12-22 | 2007-05-10 | Bayer Pharmaceuticals Corp., West Haven | Hemmung von raf-kinase unter verwendung von aryl- und heteroarylsubstituierten heterocyclischen harnstoffen |
CA2416527C (en) * | 2000-08-10 | 2009-12-22 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
-
2003
- 2003-07-16 BR BR0312913-6A patent/BR0312913A/pt not_active IP Right Cessation
- 2003-07-16 CA CA002493637A patent/CA2493637A1/en not_active Abandoned
- 2003-07-16 JP JP2004525251A patent/JP2005537290A/ja not_active Abandoned
- 2003-07-16 WO PCT/EP2003/007851 patent/WO2004013144A1/en active Application Filing
- 2003-07-16 US US10/522,253 patent/US20060135508A1/en not_active Abandoned
- 2003-07-16 AU AU2003244649A patent/AU2003244649A1/en not_active Abandoned
- 2003-07-16 EP EP03738125A patent/EP1527074A1/en not_active Withdrawn
- 2003-07-16 MX MXPA05000945A patent/MXPA05000945A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2003244649A1 (en) | 2004-02-23 |
MXPA05000945A (es) | 2005-05-16 |
EP1527074A1 (en) | 2005-05-04 |
JP2005537290A (ja) | 2005-12-08 |
US20060135508A1 (en) | 2006-06-22 |
WO2004013144A1 (en) | 2004-02-12 |
CA2493637A1 (en) | 2004-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0312913A (pt) | Ativo de biciclo-pirazóis como inibidores de cinase, processo para sua preparação e composições farmacêuticas compreendendo o mesmo | |
BR0312924A (pt) | Biciclo-pirazóis ativos como inibidores de quinase, processo para sua preparação e composições farmacêuticas compreendendo os mesmos | |
BR0215063A (pt) | Derivados de hidroxifenil-pirazol ativos como inibidores de cinase, processo para preparação dos mesmos e composições farmacêuticas compreendendo-os | |
BRPI0407544A (pt) | derivados de pirazol tetracìclicos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas que os compreendem | |
BR0212841A (pt) | Derivado ativo de aminoindazole como inibidores de cinase, processo para sua preparação e composições farmacêuticas que os contém | |
EA200400283A1 (ru) | Производные аминофталазинона, активные как ингибиторы киназ, способ их получения и содержащие их фармацевтические композиции | |
BR122019010200B8 (pt) | compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas | |
ECSP14011269A (es) | Formulaciones de anticuerpos y proteínas de alta concentración | |
EA200400289A1 (ru) | Производные аминоизоксазола, активные в качестве ингибиторов киназы | |
BRPI0408486A (pt) | derivados de biciclopirazol ativos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas compreendendo-os | |
GB0102687D0 (en) | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them | |
MXPA02012164A (es) | Derivados de tiofeno activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden. | |
BR9806870A (pt) | Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, e, uso de um composto e processo para preparar o mesmo. | |
BRPI0407375A (pt) | Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos | |
BRPI0418179A (pt) | derivados de pirrolo[2,3-b] piridina ativos como inibidores de quinase, processo para sua preparação e composições farmacêuticas os compreendendo | |
EA200400953A1 (ru) | Замещённые пиридиноны в качестве модуляторов map-киназы p38 | |
BRPI0509172A (pt) | pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento | |
BR0314760A (pt) | Compostos orgânicos | |
BR0317358A (pt) | Composto de pirrolopiridazina, processo para sua preparação, composição farmacêutica contendo o mesmo, método de prevenção ou tratamento de doenças contendo o mesmo e seu uso | |
BR9607965A (pt) | Composto composição farmacêutica e processo para tratar uma doença parasítica em um mamífero | |
PT1272199E (pt) | Terapias de combinacao com actividade de lesao vascular | |
BR0308957A (pt) | Composto, composição farmacêutica, método para o tratamento de uma inflamação ou de uma desordem associada a uma inflamação em um paciente, uso dos compostos e processo para sua preparação | |
WO2022150654A3 (en) | Antigen-binding polypeptides specific for coronaviruses and uses thereof | |
BR9705456A (pt) | Compostos heterocìclicos, processo de aminometila para sua preparação e composições farmacêuticas que os contêm. | |
BR0314180A (pt) | Aminoéteres substituìdos para o tratamento da doença de alzheimer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 6A., E 7A. ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010. |